- 1.
- 2.
- 3.
- 4.
- 5.
- 6.
Lyons A, et al. Age at first anal sex and HIV/STI vulnerability among gay men in Australia.
Sexually Transmitted Infections. 2012;88:252–e257. [
PubMed: 22246810]
- 7.
Preda M, et al. Research Report on MARA: conducted as part of the project “HIV Prevention in Most-at-Risk Adolescents”. Bucharest: University of Bucharest Romania Faculty of Sociology and Social Work, United Nations Children's Fund Romania; 2009.
- 8.
- 9.
- 10.
- 11.
- 12.
- 13.
- 14.
- 15.
Balthasar H, Jeannin A, Dubois-Arber F. First anal intercourse and condom use among men who have sex with men in Switzerland.
Archives of Sexual Behavior. 2009;38(6):1000–1008. [
PubMed: 18561013]
- 16.
- 17.
- 18.
- 19.
Priority HIV and sexual health interventions in the health sector for men who have sex with men and transgender people in the Asia-Pacific Region. Geneva: World Health Organization; 2010.
- 20.
Global AIDS response progress reporting 2012: guidelines construction of core indicators for monitoring the 2011 Political Declaration on HIV/AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2011.
- 21.
United Nations General Assembly. General Assembly Resolution 65/277 - Political Declaration on HIV/AIDS: Intensifying our Efforts to Eliminate HIV/AIDS. New York: United Nations; 2011.
- 22.
United Nations Economic and Social Council. United Nations Economic and Social Council Resolution E/2009/L.23: Joint United Nations Programme on Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(UNAIDS); Adopted 24 July 2009. New York: United Nations; 2009.
- 23.
Resolution 53/9: Achieving universal access to prevention, treatment, care and support for drug users and people living with or affected by HIV. Vienna: Commission on Narcotic Drugs; 2010.
- 24.
4th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland 22–24 June 2009: decisions, recommendations and conclusions. Geneva: Joint United Nations Programme on HIV/AIDS; 2009.
- 25.
- 26.
- 27.
- 28.
- 29.
Ellenbogen R, Rubin L. Injectable fluid silicone therapy. Human morbidity and mortality.
Journal of the American Medical Association. 1975;234(3):308–309. [
PubMed: 1174244]
- 30.
Wilson E, et al. The use and correlates of illicit silicone or “fillers” in a population-based sample of transwomen, San Francisco, 2013.
Journal of Sexual Medicine. 2014 [
PMC free article: PMC4304636] [
PubMed: 24810672]
- 31.
Ball A. Policies and interventions to stem HIV-1 epidemics associated with injecting drug use. In: Stimson GV, Des Jarlais DC, Ball A, editors. Drug injecting and HIV infection. London: UCL Press; 1998. 1998.
- 32.
Tool for setting and monitoring targets for prevention, treatment and care for HIV among men who have sex with men, sex workers and transgender people. Geneva: World Health Organization; Forthcoming.
- 33.
Institute of Medicine of the National Academies.
Preventing HIV infection among injecting drug users in high risk countries: an assessment of the evidence. Washington, DC: National Academy of Sciences; 2007. [28 February 2014].
http://www.nap.edu/openbook.php?record_id=11731
.
- 34.
- 35.
- 36.
- 37.
- 38.
Palmateer N, et al. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: a review of reviews.
Addiction. 2010;105:844–859. [
PubMed: 20219055]
- 39.
- 40.
Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs.
Journal of Infectious Diseases. 2011;204:74–83. [
PMC free article: PMC3105033] [
PubMed: 21628661]
- 41.
Hagan H, et al. An interview study of participants in the Tacoma, Washington, syringe exchange.
Addiction. 1993;88(12):1691–1697. [
PubMed: 8130708]
- 42.
National Research Council. Preventing HIV infection among injecting drug users in high risk countries: an assessment of the evidence. Washington, DC: The National Academies Press; 2006.
- 43.
Schechter MT, et al. Do needle exchange programmes increase the spread of HIV among injection drug users?: an investigation of the Vancouver outbreak.
AIDS. 1999;13(6):F45–51. [
PubMed: 10397556]
- 44.
Watters JK, et al. Syringe and needle exchange as HIV/AIDS prevention for injection drug users.
Journal of the American Medical Association. 1994;271(2):115–120. [
PubMed: 8264065]
- 45.
- 46.
- 47.
- 48.
- 49.
- 50.
- 51.
Ward J, Mattick RP, Hall W, editors.
Methadone maintenance treatment and other opioid replacement therapies. Sydney: Harwood Academic Publishers; 1998. [28 February 2014].
http://www.drugsandalcohol.ie/3767
.
- 52.
- 53.
- 54.
- 55.
- 56.
- 57.
- 58.
- 59.
- 60.
Rolling out of opioid substitution treatment (OST) in Tihar prisons, India: scientific report. Vienna: United Nations Office on Drugs and Crime; 2013.
- 61.
- 62.
- 63.
- 64.
- 65.
- 66.
- 67.
Degenhardt L, Hall W. Extent of illicit drug use and dependence, and their contribution to the global burden of disease.
Lancet. 2012;379(9810):55–70. [
PubMed: 22225671]
- 68.
- 69.
Guidelines on the management of opioid overdose in the community setting. Geneva: World Health Organization; Forthcoming.
- 70.
Sawyer SM, et al. Adolescence: a foundation for future health.
Lancet. 2012;379(9826):1630–1640. [
PubMed: 22538178]
- 71.
- 72.
Guidance brief: HIV interventions for most-at-risk young people. New York: Inter-Agency Task Team on HIV and Young People; 2007.
- 73.
Interagency Youth Working Group. Young people most at risk of HIV: a meeting report and discussion paper from the Interagency Youth Working Group, United States Agency for International Development, Joint United Nations Programme on HIV/AIDS Inter-Agency Task Team on HIV and Young People, and FHI. Research Triangle Park, NC, USA: FHI; 2010.
- 74.
- 75.
- 76.
Choopanya K. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Lancet. 2013;381(9883):2083–2090. [
PubMed: 23769234]
- 77.
Vanichseni S, et al. HIV-associated risk behaviour among injecting drug users participating in an HIV pre-exposure prophylaxis trial in Bangkok, Thailand; Poster presented at the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention; Kuala Lumpur, Malaysia. 30 June–3 July 2013; MOLBPE27.
- 78.
Thai Drug Users Network; Thai AIDS Treatment Action Group; Treatment Action Group.
U.S. Centers for Disease Control and Prevention (CDC) sponsored HIV preexposure prophylaxis (PrEP) trial among Thai injection drug users marred by lack of response to community concerns. Bangkok: Thai Treatment Action Group; Jun 26, 2013. [29 April 2014].
http://www.treatmentactiongroup.org/hiv/Bangkok-prep-statement
.
- 79.
- 80.
- 81.
- 82.
Bailey R, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial.
Lancet. 2007;369:643–656. [
PubMed: 17321310]
- 83.
Gray R, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial.
Lancet. 2007;369:657–666. [
PubMed: 17321311]
- 84.
- 85.
Gray R, et al. The effectiveness of male circumcision for HIV prevention and effects on risk behaviors in a posttrial follow-up study.
AIDS. 2012;26(5):609–615. 610.1097/QAD.1090b1013e3283504a3283503f. [
PMC free article: PMC4296667] [
PubMed: 22210632]
- 86.
HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy-makers and managers. Geneva: World Health Organization; 2013. [
PubMed: 25032477]
- 87.
- 88.
- 89.
- 90.
Joint statement on scaling up voluntary community-based HIV testing and counselling for key populations in Asia and the Pacific. Bangkok: Asia Pacific Network of People Living with HIV/AIDS, Asian Network of People who Use Drugs, Coalition of Asia Pacific Regional Networks on HIV/AIDS, Joint United Nations Programme on HIV/AIDS, World Health Organization, Asia Pacific Network of Sex Workers, Asia Pacific Coalition of Male Sexual Health, and United States President's Emergency Plan for AIDS Relief; 2013. [22 May 2014].
http://www.wpro.who.int/hiv/Joint_Statement_on_scalling_up_community_based_testing_in_AP.pdf
.
- 91.
- 92.
- 93.
- 94.
- 95.
Handbook for improving HIV testing and counselling services: field-test version. Geneva: World Health Organization; 2010.
- 96.
- 97.
- 98.
- 99.
Braunstein SL, et al. HIV diagnosis, linkage to HIV care, and HIV risk behaviors among newly diagnosed HIV-positive female sex workers in Kigali, Rwanda.
Journal of Acquired Immune Deficiency Syndromes. 2011;57(4):e70–76. [
PubMed: 21407083]
- 100.
- 101.
Buckingham E, Schrage E, Cournos F. Why the treatment of mental disorders is an important component of HIV prevention among people who inject drugs.
Advances in Preventive Medicine. 2013 [
PMC free article: PMC3562640] [
PubMed: 23401785]
- 102.
Wouters E, et al. Impact of community-based support services on antiretroviral treatment preogramme delivery and outcomes in resource-limited countries: a synthetic review.
BMC Health Services Research. 2012;12:194. [
PMC free article: PMC3476429] [
PubMed: 22776682]
- 103.
Milloy MJ, Montaner J, Wood E. Barriers to HIV treatment among people use injection drugs: implications for “treatment as prevention”
Current Opinion in HIV/AIDS. 2012;7(4):332–338. [
PubMed: 22576468]
- 104.
- 105.
- 106.
Govindasamy D, et al. Linkage to HIV care from a mobile testing unit in South Africa by different CD4 count strata.
Journal of Acquired Immune Deficiency Syndromes. 2011;58(3):344–352. [
PMC free article: PMC3805962] [
PubMed: 21836524]
- 107.
Roberson DW, White BL. Factors influencing adherence to antiretroviral therapy for HIV infected female inmates.
Journal of the Association of Nurses in AIDS Care. 2009;20(1):50–61. [
PMC free article: PMC4592129] [
PubMed: 19118771]
- 108.
Small W, et al. The impact of incarceration upon adherence to HIV treatment among HIV-positive injection drug users: a qualitative study.
AIDS Care. 2009;21(6):708–714. [
PubMed: 19806487]
- 109.
Shalihu N, et al. Namibian prisoners describe barriers to HIV antiretroviral therapy adherence.
AIDS Care. 2014;26(8) [
PubMed: 24499371]
- 110.
- 111.
Fontana L, Beckerman A. Recently released with HIV/AIDS: primary care treatment needs and experiences.
Journal of Health Care for the Poor and Underserved. 2007;18(3):699–714. [
PubMed: 17675724]
- 112.
Wohl DA, et al. Intensive case management before and after prison release is no more effective than comprehensive pre-release discharge planning in linking HIV-infected prisoners to care: a randomized trial.
AIDS Behavior. 2011;15(2):356–364. [
PMC free article: PMC3532052] [
PubMed: 21042930]
- 113.
Nunn A, Cornwall A, et al. Linking HIV-positive jail inmates to treatment, care, and social services after release: results from a qualitative assessment of the COMPASS program.
Journal of Urban Health. 2010;87(6):954–968. [
PMC free article: PMC3005089] [
PubMed: 21046470]
- 114.
Zaller ND, et al. Linkage to treatment and supportive services among HIV-positive ex-offenders in Project Bridge.
Journal of Health Care for the Poor and Underserved. 2008;19(2):522–531. [
PubMed: 18469423]
- 115.
Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward.
Lancet. 2010;376(9738):355–366. [
PubMed: 20650513]
- 116.
IMAI one-day orientation on adolescents living with HIV: participants manual and facilitator guide. Geneva: World Health Organization; 2010.
- 117.
Adolescent HIV care and treatment: a training curriculum for health workers. New York: International Center for AIDS Care and Treatment Programs; 2012.
- 118.
Toolkit for transition of care and other services for adolescents living with HIV. Arlington, VA, USA: AIDSTAR-One; 2013.
- 119.
- 120.
- 121.
Benhamou Y, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients.
Hepatology. 1999;30:1054–1058. [
PubMed: 10498659]
- 122.
- 123.
- 124.
- 125.
WHO policy on TB infection control in health-care facilities, congregate settings and households. Geneva: World Health Organization; 2009. [
PubMed: 24432438]
- 126.
- 127.
van den Hof S, et al. Converging risk factors but no association between HIV infection and multidrug-resistant tuberculosis in Kazakhstan.
International Journal of Tuberculosis and Lung Disease. 2013;17(4):526–531. [
PubMed: 23485387]
- 128.
Akksilp S, et al. Multi-drug resistant TB and HIV in Thailand: overlapping, but not independently associated risk factors.
Southeast Asian Journal of Tropical Medicine and Public Health. 2009;40(6):1264. [
PubMed: 20578461]
- 129.
Sterling, et al. A multi-state outbreak of tuberculosis among members of a highly mobile social network: implications for tuberculosis elimination.
International Journal of Tuberculosis and Lung Disease. 2000;11(9):1066–1073. [6 June 2014];
http://www.ncbi.nlm.nih.gov/pubmed/11092720
. [
PubMed: 11092720]
- 130.
- 131.
Lönnroth K, et al. Drivers of tuberculosis epidemics: the role of risk factors and social determinants.
Social Science & Medicine. 2009;68(12):2240–2246. Epub 2009 Apr 23. [
PubMed: 19394122] [
CrossRef]
- 132.
Levy MH, Reyes H, Coninx R. Overwhelming consumption in prisons: human rights and tuberculosis control.
Health and Human Rights. 1999;4:166–191. [
PubMed: 10438559]
- 133.
- 134.
Conover C, et al. Outbreak of multidrug-resistant tuberculosis at a methadone treatment program.
International Journal of Tuberculosis and Lung Disease. 2001;5:59–64. [
PubMed: 11263518]
- 135.
- 136.
- 137.
- 138.
- 139.
- 140.
- 141.
- 142.
- 143.
Protocol 4. Management of tuberculosis and HIV coinfection, 2013 revision. Copenhagen: WHO Regional Office for Europe; 2013.
- 144.
Friedland G. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.
Journal of Acquired Immune Deficiency Syndromes. 2010;55:S37–S42. [
PMC free article: PMC4505738] [
PubMed: 21045598]
- 145.
- 146.
Larney S, et al. Incidence and prevalence of hepatitis C in prisons and other closed settings: results of a systematic review and meta-analaysis.
Hepatology. 2013;58(4):1215–1224. [
PMC free article: PMC3723697] [
PubMed: 23504650]
- 147.
Weinbaum C, et al. Prevention and control of infections with hepatitis viruses in correctional settings.
Morbidity and Mortality Weekly Report. 2003;52(RR-1):1–34. [
PubMed: 12562146]
- 148.
Semaille C, et al. Prevalence of human immunodeficiency virus and hepatitis C virus among French prison inmates in 2010: a challenge for public health policy.
Euro Surveillance. 2013;18(28) 20524. [
PubMed: 23870097]
- 149.
Adjei AA, et al. Prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus and syphilis among prison inmates and officers at Nsawam and Accra, Ghana.
Journal of Medical Microbiology. 2006;55(Pt 5):593–597. [
PubMed: 16585647]
- 150.
Barros LA, et al. Epidemiology of the viral hepatitis B and C in female prisoners of Metropolitan Regional Prison Complex in the State of Goiás, Central Brazil.
Revista da Sociedade Brasileira de Medicina Tropical. 2013;46(1):24–29. [
PubMed: 23563821]
- 151.
Deng LP, et al. Impact of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.
World Journal of Gastroenterology. 2009;15:996–1003. [
PMC free article: PMC2653408] [
PubMed: 19248201]
- 152.
- 153.
- 154.
Rockstroh J, et al. Increases in acute hepatitis C (HCV) incidence across Europe: which regions and patient groups are affected?; Paper presented at the 11th International Congress on Drug Therapy in HIV Infection (HIV11); Glasgow. 11–15 November 2012; abstract O242.
- 155.
- 156.
- 157.
Pineda JA, et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis.
Hepatology. 2005;41:779–789. [
PubMed: 15800956]
- 158.
- 159.
Walsh N, et al. The silent epidemic: responding to viral hepatitis among people who inject drugs. In: Cook C, editor.
Global state of harm reduction 2010. London: International Harm Reduction Association; 2011. [28 February 2014].
http://www.ihra.net/files/2010/06/15/Chapter_3.1Web_.pdf
.
- 160.
- 161.
Topp L, et al. A randomised controlled trial of financial incentives to increase hepatitis B vaccination completion among people who inject drugs in Australia.
Preventive Medicine. 2013;57(4):297–303. [
PubMed: 23639625]
- 162.
Joska JA, et al. Severe mental illness and retention in anti-retroviral care: a retrospective study.
AIDS Behavior. 2014:1–9. [
PubMed: 24515624]
- 163.
Global health estimates 2013 summary tables: DALYs, YLLs and YLDs by cause, age and sex by WHO regional group and World Bank income classification, 2000-2012 (provisional estimates). Geneva: World Health Organization; 2014.
- 164.
- 165.
- 166.
- 167.
- 168.
- 169.
La Vigne NG, et al. Preventing violence and sexual assault in jail: a situational crime prevention approach. Justice Policy Center Brief. 2011
- 170.
Yap L, et al. The decline in sexual assaults in men's prisons in New South Wales: a systems approach.
Journal of Interpersonal Violence. 2011;26(15):3157–3181. [
PubMed: 21282119]
- 171.
Ravi A, Blankenship KM, Altice FL. The association between history of violence and HIV risk: a cross-sectional study of HIV-negative incarcerated women in Connecticut.
Women's Health Issues. 2007;17(4):210–216. [
PubMed: 17570681]
- 172.
Kerbs JJ, Jolley JM. Inmate-on-inmate victimization among older male prisoners. Crime and Delinquency. 2007;31(5):385–393.
- 173.
- 174.
- 175.
De Vuyst H, et al. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy.
European Journal of Cancer Prevention. 2008;17:545–554. [
PubMed: 18941376]
- 176.
Denny L, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women.
Obstetrics and Gynecology. 2008;111:1380–1387. [
PubMed: 18515522]
- 177.
Firnhaber C, et al. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa.
Cancer Causes & Control. 2010;21:433–443. [
PMC free article: PMC2835728] [
PubMed: 19949850]
- 178.
- 179.
- 180.
Grulich AE, et al. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis.
Lancet. 2007;370(9581):59–67. [
PubMed: 17617273]
